Welcome to our dedicated page for SI-BONE SEC filings (Ticker: SIBN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on SI-BONE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into SI-BONE's regulatory disclosures and financial reporting.
SI-BONE (SIBN) reported an insider transaction by CEO and Director Laura A. Francis. She sold 5,411 shares of common stock on 11/11/2025 at a weighted‑average price of $17.0591, effected under a Rule 10b5-1 trading plan dated December 13, 2024.
After the sale, 356,730 shares were held indirectly by a trust, and 419,704 shares were held directly. The direct figure includes 396,297 shares issuable upon settlement of restricted stock units.
SI-BONE (SIBN) director Jeffrey W. Dunn reported option exercises and related sales on 11/11/2025. He exercised stock options at $4.32 for 23,148 shares and 56,852 shares, then sold the same amounts at $18.95 per share pursuant to a Rule 10b5-1 trading plan dated May 7, 2025.
Following these transactions, he directly held 10,307 shares. He also had indirect ownership of 118,874 shares held by The Jeffrey W. Dunn Living Trust. The direct total includes 10,307 shares issuable upon settlement of restricted stock units, each representing one share of common stock. The option awards referenced vest in equal monthly installments over four years, subject to continued service.
SI-BONE (SIBN) reported a Form 4 for CFO Anshul Maheshwari. On 11/11/2025, he sold 2,601 shares of common stock at a weighted-average price of $18.3333, executed under a Rule 10b5-1 trading plan dated December 13, 2024. Following the sale, he beneficially owns 208,533 shares, which include 150,203 shares issuable upon settlement of restricted stock units. Ownership is listed as direct.
SI-BONE (SIBN) reported Q3 2025 results with strong top-line growth and improved profitability trends. Revenue was $48,656,000, up 20.6% from $40,340,000, driven largely by higher U.S. case volumes. Gross margin expanded to 79.8% from 79.1%, lifting gross profit to $38,846,000.
Operating expenses rose to $44,229,000, primarily from higher sales and marketing and general and administrative costs, resulting in a smaller operating loss of $5,383,000 versus $7,633,000 a year ago. Net loss narrowed to $4,566,000 compared with $6,575,000, and net loss per share improved to $0.11 from $0.16.
Liquidity remained solid with cash and cash equivalents of $26,487,000 and short-term investments of $119,257,000. Inventory increased to $35,727,000 to support demand. Long-term borrowings were $35,540,000. Shares outstanding were 43,391,254 as of November 4, 2025.
SI-BONE, Inc. (SIBN) announced board and governance updates. Director Daniel Wolf resigned from the Board on November 6, 2025, and the company stated his resignation was not due to any disagreement with the company or management. Following his departure, the Board size was reduced from nine to eight, and current director Thomas A. West was appointed to the Audit Committee.
SI-BONE and Mr. Wolf entered into a 12-month consulting agreement covering marketing, strategy, business development and other corporate matters. The agreement accelerates vesting of 8,675 restricted stock units granted to Mr. Wolf on June 5, 2025, making them fully vested as of November 6, 2025, and provides cash compensation at an hourly rate set in applicable statements of work. The company also furnished a press release announcing results for the quarter ended September 30, 2025 as Exhibit 99.1.
SI‑BONE (SIBN) director reported a routine insider transaction. On 11/03/2025, the reporting person sold 293 shares of common stock at a weighted average price of $14.8038. The filing states this was a sell‑to‑cover to satisfy tax withholding from vesting RSUs, not a discretionary trade.
Following the transaction, the filer beneficially owns 10,831 shares directly and 118,350 shares indirectly via a trust. The direct holdings include 10,307 shares issuable upon settlement of restricted stock units, each representing one share.
SI-BONE, Inc. (SIBN) reported insider sales by Michael A. Pisetsky, SVP, Ops & Adm/Chief Legal Officer, on 10/02/2025. The Form 4 shows a total of 3,128 shares of common stock sold across multiple trades to satisfy tax withholding on vesting restricted stock units; these sales are described as a "sell to cover" and not discretionary. Reported weighted average prices per transaction are $14.255, $14.1053, and $14.2537, and the filing lists 256,556, 256,522, and 255,224 shares beneficially owned after each reported sale line. The filing also discloses 132,362 shares issuable on settlement of restricted stock units retained by the reporting person.
SI-BONE, Inc. Chief Financial Officer Anshul Maheshwari reported selling a total of 3,311 shares of common stock on October 2, 2025, in open-market transactions at weighted average prices of $14.2237 and $14.1711 per share.
The company states these shares were sold solely to cover tax withholding obligations arising from the vesting of restricted stock units under a "sell to cover" arrangement and did not represent a discretionary trade by the CFO. After these transactions, Maheshwari directly holds 211,134 shares of common stock, including 150,203 shares issuable upon settlement of restricted stock units.
SI-BONE, Inc. (SIBN) reported an insider transaction by its President, Commercial Ops, Anthony J. Recupero. On 10/02/2025, he sold 1,557 shares at a weighted average price of $14.2374 and 1,754 shares at a weighted average price of $14.27.
The filing states these were sell-to-cover sales to satisfy tax withholding upon RSU vesting and were not discretionary trades. Following the transactions, he beneficially owned 271,977 shares. This total includes 141,167 shares issuable upon settlement of restricted stock units, with each RSU representing one share.
Anthony J. Recupero, President, Commercial Ops of SI-BONE, Inc. (SIBN), reported routine sales on 08/18/2025 to cover tax withholding arising from vested restricted stock units. The Form 4 shows two disposition entries totaling 3,833 shares sold (2,126 and 1,707 shares) at weighted-average prices of $15.627 and $15.6134, executed in multiple trades within price ranges noted in the footnotes. After the reported transactions, the filing shows 275,288 shares beneficially owned and discloses 147,947 shares issuable upon settlement of outstanding restricted stock units. The filing identifies the sales as "sell to cover" for tax obligations and not discretionary trading.